Drug Trial Radar · NCT04125836
A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
Last checked: Nov 19, 2026Latest source record: Dec 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
135
Actual
Start
Oct 10, 2019
Primary completion
Apr 24, 2025
Study completion Apr 24, 2025
Sponsor
- Lead sponsor
- Camurus ABIndustry
- Sponsor type
- Industry
- First posted
- Oct 14, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this trial is to assess the long-term safety and efficacy of CAM2029 in patients with acromegaly. Patients will be administered CAM2029 subcutaneously once monthly during 12 months. Patients fulfilling trial NCT04076462 will be offered to continue with open-label treatment week 24-52 in this trial. Patients completing the main part of the trial will be offered 52 weeks continued open-label treatment in an extension part.
Conditions
- Acromegaly
Interventions
CAM2029 (octreotide subcutaneous depot)Drug
Octreotide subcutaneous depot for monthly injections in acromegaly patients
Primary outcomes
What the sponsor says the trial is designed to measure.
- Characterization of adverse events (AEs)Time frame: Week 0-52
Locations
68 sites in 11 countries. Site status is shown where the registry gives one.
UCLA Department of Medicine Division of Endocrinology
Los Angeles, California
Stanford University Medical Center
Palo Alto, California
Prufen Clinical Research LLC
Miami, Florida
University of Michigan
Ann Arbor, Michigan
Mayo Clinic
Rochester, Minnesota
Washington University in St. Louis, School of Medicine
St Louis, Missouri
Palm Research Center
Las Vegas, Nevada
Columbia University Medical Center
New York, New York
University of Cincinnati
Cincinnati, Ohio
Thomas Jefferson University
Philadelphia, Pennsylvania
Allegheny Endocrinology Associates
Pittsburgh, Pennsylvania
Research Institute of Dallas
Dallas, Texas
Universitätsklinikum Essen
Essen, Germany
Universitätsklinikum Frankfurt, Medizinische Klinik 1, Schwerpunkt Endokrinologie, Diabetologie, Ernährungsmedizin
Frankfurt, Germany
Universitätsklinikum Freiburg
Freiburg im Breisgau, Germany
Universitätsklinikum Leipzig
Leipzig, Germany
LMU Clinic of University of Munich, Medical Clinic and Polyclinic IV
Munich, Germany
Medicover Neuroendokrinologie
Munich, Germany
Medicover Oldenburg MVZ
Oldenburg, Germany
General Hospital of Athens "Laiko", Endocrinology University Clinic
Athens, Greece
Aretaeio University Hospital Endocrinology Department, Faculty of Diabetes and Metabolism
Athens, Greece
General Hospital of Thessaloniki "Ippokratio"
Thessaloniki, Greece
Military Health Center, 2nd Department of Internal Medicine
Budapest, Hungary
SZTE ÁOK I.sz. Belgyógyászati Klinika
Szeged, Hungary
IRCCS Policlinico San Martino
Genova, Italy
Azienda Universitaria "Federico II"
Naples, Italy
Azienda Ospedaliera Padova, Department of Internal medicine
Padova, Italy
Policlinic Gemelli University Hospital IRCCS, Department of Endocrinology
Roma, Italy
AOUI Verona, Policlinic of GB Rossi
Verona, Italy
Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie
Krakow, Poland
Centrum Nowoczesnych Terapii "Dobry Lekarz"
Krakow, Poland
Amicare Sp. z o.o. Sp. K.
Lodz, Poland
Piekarskie Centrum Medyczne, Szpital Miejski
Piekary Śląskie, Poland
Interregional Clinical Diagnostic Center
Kazan', Russia
"Atlas" Medical Center
Moscow, Russia
Sechenov Moscow First State Medical University
Moscow, Russia
Vladimirsky Moscow Regional Research Clinical Institute
Moscow, Russia
Novosibirsk State Regional Clinical Hospital
Novosibirsk, Russia
Interregional Clinical Diagnostic Center
Ryazan, Russia
Saratov Regional Clinic Hospital
Saratov, Russia
Showing 40 of 68 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.